KR102228028B1 - Composition for preventing or treating inflammatory bowel disease comprising mixture of herbal extracts of indigo pulverata levis, broussonetia kazinoki, and juglans mandshurica - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel diseases, containing a complex herbal medicine extract of Persicaria tinctorium, Broussonetia kazinoki, and/or Juglans mandshurica. In addition, the present invention relates to a food composition or a feed composition for preventing or alleviating inflammatory bowel diseases, containing the herbal medicine extract.

Description

[COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE COMPRISING MIXTURE OF HERBAL EXTRACTS OF INDIGO PULVERATA LEVIS, BROUSSONETIA KAZINOKI, AND　}

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease comprising a complex herbal extract of Cheongdae, Japanese oak, and Phalaenopsis as an active ingredient. In addition, the present invention relates to a food composition or feed composition for preventing or improving inflammatory bowel disease comprising the herbal extract as an active ingredient.

Inflammatory bowel disease (IBD) is a disease that causes chronic inflammation of the intestine of unknown cause. It has a clinical progression with repeated exacerbation and improvement, and ulcerative colitis and Crohn's disease are representative diseases. The cause or pathophysiology of inflammatory bowel disease is not yet clearly known, but it is estimated that genetic factors, environmental factors such as intestinal bacteria and food, and immunological factors are complexly involved in the development mechanism. Persistent or inappropriate activation of the intestinal immune system plays an important role in the pathophysiology of chronic mucosal inflammation, in particular, by infiltration of neutrophils, macrophages, lymphocytes and mast cells, eventually leading to mucosal destruction and ulcers. Infiltrated and activated neutrophils are an important cause of reactive oxygen species and reactive nitrogen species, and these active species are cytotoxic substances that induce oxidative stress that degrades crosslinking proteins, lipids and nucleic acids, and causes epithelial dysfunction and damage. do.

The fundamental treatment for inflammatory bowel disease has not yet been established, so drugs that can relieve symptoms are being used. Mainly, 5-aminosalicylic acid (5-ASA) drugs that block the production of prostaglandins, such as sulfasalazine, are used, or immunosuppressants such as steroids are used.

Sulfasalazine is likely to cause side effects or adverse effects such as fullness, headache, rash, liver disease, leukopenia, agranulocytosis, and male infertility. In addition, it is unclear whether sulfasalazine has a sufficient inhibitory effect on recurrence in patients with incisions in the intestine or patients with remission.

Steroid-type immunosuppressants are adrenal cortical steroids, which are recognized for their short-term effects, but cannot improve long-term prognosis. In addition, in terms of side effects such as induced infectious diseases, secondary adrenal insufficiency, peptic ulcer, diabetes, mental disorders, steroidal nephropathy, etc., there is a limitation that should be used only in acute cases.

That is, since there is still no reliable therapy for inflammatory bowel disease, there is a need to develop a new therapeutic agent that has no side effects, is inexpensive, and has excellent therapeutic effect. For example, a composition for preventing or treating inflammatory bowel disease using natural extracts (Korea Registered Patent No. 10-1710730) and the like are being developed.

On the other hand, Cheongdae ( Indigo Pulverata levis ) is a powder obtained by fermenting the leaves of the annual herb of the family Nodifolidae, also known as indigo. Indigo is native to China and India, and is a representative plant used as a blue dye for dyeing fabrics and threads. It is a dye obtained from the leaves in July-August, and is used for dyeing by techniques such as the raw juice method and the half-mul method. Cheongdae's taste is salty, its nature is cold, and it is known to have anticancer, cheongyeol, and detoxification. Blackthorn ( Broussonetia kazinoki ) is a deciduous broad-leaved arboreous tree of the Moraceae family, and it is a male and female tree, and it blooms at the same time while its leaves appear in spring. The fruit is a ball-shaped drupe that resembles a snake strawberry, ripens around September, and grows naturally around cultivated land or in the sunny side of the foot of the mountain. The bark is used as a material for making paper in Korea, China, and Japan, and the fruit is called'jeosil'or'gusuja' and is used as a medicinal material, and young leaves are sometimes eaten. The sputum tree ( Juglans mandshurica ) is classified as a family or walnut family, and exists in the form of a tree or shrub, and is native to the Americas, Eurasia or South Asia. It mainly lives in the northeastern part of Korea or northeastern China, and is used as a medicinal plant and herbal medicinal material, and the fruit ripened in September-October is used for medicinal or edible use.

However, until now, it has not been known whether or not extracts of complex herbal medicines from Cheongdae, Japanese oak, and sputum can be effectively used in the treatment of inflammatory bowel disease. In this regard, the inventors of the present invention have conducted continuous research in order to develop natural products having therapeutic efficacy for inflammatory bowel disease. The present invention has been completed.

Korean Patent Registration No. 10-1710730

An object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising a complex herbal extract of Cheongdae, Japanese oak and/or Phalaenopsis as an active ingredient.

The present invention is to provide a food composition for preventing or improving inflammatory bowel disease, comprising a complex herbal extract of Cheongdae, Japanese oak and/or Phalaenopsis as an active ingredient.

An object of the present invention is to provide a feed composition for preventing or improving inflammatory bowel disease, comprising a complex herbal extract of Cheongdae, Japanese oak and/or Phalaenopsis as an active ingredient.

The present invention is (1) Cheongdae; And (2) it provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising one or more herbal extracts selected from the group consisting of oak and sputum.

In one embodiment, the herbal extract may be a mixture of extracts extracted from each herbal medicine, or extracted from a mixture of herbal medicines.

In one embodiment, the mulberry extract may be a mulberry stem extract, a mulberry fruit extract, a mulberry root extract, or a mulberry leaf extract, and preferably may be a mulberry leaf extract.

In one embodiment, the sputum tree extract may be a sputum tree stem extract, a sputum tree fruit extract, a sputum tree root extract, or a sputum tree leaf extract, preferably a sputum tree fruit extract.

In one embodiment, the herbal extract may be extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, and a mixed solvent thereof. Preferably, it is 0.01% to 90% ethanol extract, and most preferably, it is 60% to 80% ethanol extract.

In one embodiment, the pharmaceutical composition may include extracts of herbal medicines of Cheongdae, Japanese oak and Sputum. The blending weight ratio of the Cheongdae, Japanese oak, and sputum may be 1:0.1 to 10: 0.1 to 10, preferably 1: 0.5 to 2: 0.5 to 2, more preferably 1: 1: 1.

In one embodiment, the pharmaceutical composition may suppress a decrease in the length or weight of the large intestine due to inflammatory bowel disease.

In another embodiment, the pharmaceutical composition may inhibit an increase in the length or weight of the spleen due to inflammatory bowel disease.

The present invention is (1) Cheongdae; And (2) it provides a food composition for preventing or improving inflammatory bowel disease, comprising one or more herbal extracts selected from the group consisting of oak and sputum.

The present invention is (1) Cheongdae; And (2) it provides a feed composition for preventing or improving inflammatory bowel disease, comprising one or more herbal extracts selected from the group consisting of mulberry and sputum.

The pharmaceutical composition comprising the complex herbal extracts of Cheongdae, Japanese oak and/or Phalaenopsis of the present invention as an active ingredient exhibits an excellent therapeutic effect against inflammatory bowel disease, and thus can be used as a novel therapeutic agent.

In addition, the pharmaceutical composition of the present invention can be used as a safe therapeutic agent to reduce side effects of existing therapeutic agents by including a natural product as an active ingredient.

1 and 2 show changes in the weight of mice in each experimental group.
3 and 4 show the length of the large intestine of mice in each experimental group.
5 shows the weight of the large intestine of mice in each experimental group.
6 shows the weight and length of the spleen of mice in each experimental group.
7 and 8 show the results of measuring disease activity (DAI) of mice in each experimental group.

Hereinafter, embodiments and examples of the present disclosure will be described in detail with reference to the accompanying drawings so that those of ordinary skill in the art may easily implement the present disclosure. However, the present application may be implemented in various forms and is not limited to the embodiments and examples described herein.

In the entire specification of the present application, when a certain part "includes" a certain constituent element, it means that other constituent elements may be further included rather than excluding other constituent elements unless otherwise specified.

(1) Cheongdae; And (2) it relates to a composition for the prevention, treatment or improvement of inflammatory bowel disease, comprising one or more herbal extracts selected from the group consisting of oak and sputum. The composition may be a pharmaceutical composition, a food composition or a feed composition.

In one embodiment, the mulberry extract may be a mulberry stem extract, a mulberry fruit extract, a mulberry root extract, or a mulberry leaf extract, and preferably may be a mulberry leaf extract.

In one embodiment, the sputum tree extract may be a sputum tree stem extract, a sputum tree fruit extract, a sputum tree root extract, or a sputum tree leaf extract, preferably a sputum tree fruit extract.

The term "herbal extract" or "complex herbal extract" as used herein is an active ingredient of the pharmaceutical composition of the present invention, including extracts extracted from herbal medicines of Cheongdae, Japanese oak and/or Sputum, or from a mixture of these herbal medicines. It may contain the extracted extract.

In one embodiment, the pharmaceutical composition may include extracts of herbal medicines of Cheongdae, Japanese oak and Sputum. The blending weight ratio of the Cheongdae, Japanese oak, and sputum may be 1:0.1 to 10: 0.1 to 10, preferably 1: 0.5 to 2: 0.5 to 2, more preferably 1: 1: 1.

When the herbal extract of the present invention is used together with an additional active ingredient, the herbal extract and the additional active ingredient may be administered simultaneously as one formulation, or may be administered simultaneously or sequentially as separate formulations.

In addition, the composition of the present invention may be used alone or in combination with surgery, hormone therapy, drug therapy, or methods of using a biological response modifier to treat inflammatory bowel disease.

The herbal extract used in the present invention can be obtained using a conventional extraction solvent known in the art. As the extraction solvent, a polar solvent or a non-polar solvent may be used. Polar solvents include water, C1 to C6 alcohols (eg, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol and normal-butanol, etc.), acetic acid, or a mixture of the polar solvents. Non-polar solvents include acetone, acetonitrile, ethyl acetate, methyl acetate, butyl acetate, fluoroalkane, hexane, ether, chloroform, dichloromethane, or mixtures of the above non-polar solvents.

In one embodiment, the herbal extract may be extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, and a mixed solvent thereof. Preferably, it is 0.01% to 90% ethanol extract, most preferably 60% to 80% ethanol extract.

The herbal extract used in the present invention may be extracted through hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction, or conventional extraction methods known in the art.

The term "extract" as used herein means commonly used as a crude extract in the art, but also includes a fraction obtained by further fractionating the extract in a broad sense. That is, the herbal extract includes not only those obtained by using the above-described solvent, but also those obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatographs (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the herbal extract of the present invention.

The term "prevention" as used herein refers to any action that suppresses or delays the onset of inflammatory bowel disease by administration of the composition according to the present invention, and "treatment" refers to suspicion of inflammatory bowel disease and It refers to any action in which symptoms of an affected individual are improved or beneficially altered. As used herein, the term “improvement” refers to any action that at least reduces the severity of a parameter, such as a symptom, associated with the condition being treated by administration of a composition comprising an extract of the present invention.

In one embodiment, the composition may be to inhibit a decrease in the length or weight of the large intestine.

In another embodiment, the composition may be one that inhibits an increase in the length or weight of the spleen.

The food composition of the present invention includes health functional foods and health foods. The food composition of the present invention can be taken for a long time.

The food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like.

The present invention is to be described in more detail through the following examples, but the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[ Manufacturing example One]

Preparation of single herbal extract

Washed and dried blue daisy (Indigo Pulverata Levis ), black oak (Broussonetia kazinoki) leaves, and sputum ( Juglans) mandshurica ) fruit was used by round or pulverizing according to the herbal medicine. Extracted for 72 hours at room temperature by adding a 10-fold 70% ethanol (v/v) aqueous solution to each herbal medicine of Cheongdae, mulberry leaves, and sputum fruit. The extract was filtered and then concentrated under reduced pressure at 50 to 65°C to obtain a powdery single herbal extract, and the following experiment was performed based on the obtained extract.

[ Example One]

Experimental group And control (1)

8-week-old C57BL/6 male mice were purchased, pre-raised for 1 week, and then randomly divided into 7 groups of 8 mice as follows to conduct the experiment.

2.5% Dextran Sulfate Sodium (DSS) diluted in sterile water was administered negatively for a total of 8 days, and 5-ASA, a treatment for inflammatory bowel disease, or each extract was orally administered for a total of 10 days from 2 days before DSS administration. .

i) Normal group: oral administration of sterile water

ii) negative control: 2.5% DSS administration

iii) Positive control: 2.5% DSS administration + 5-aminosalicylic acid (5-ASA) administered orally at a concentration of 100 mg/kg

iv) Experimental group 1-1: 2.5% DSS administration + 20mg of Cheongdae extract orally administered at a concentration of 50mg/kg

v) Experimental group 1-2: 2.5% DSS administration + 10 mg of Cheongdae extract and 10 mg of oak leaf extract were mixed and administered orally at a concentration of 50 mg/kg

vi) Experimental Group 1-3: 2.5% DSS administration + 10 mg of Cheongdae extract and 10 mg of sputum fruit extract were mixed and administered orally at a concentration of 50 mg/kg

vii) Experimental group 1-4: 2.5% DSS administration + 10 mg of Cheongdae extract, 10 mg of oak leaf extract, and 10 mg of sputum fruit extract were mixed and administered orally at a concentration of 75 mg/kg

[ Example 2]

Experimental group And control (2)

Six-week-old C57BL/6N male mice were purchased, pre-raised for one week, and then randomly divided into 8 groups of 8 mice as follows to conduct the experiment.

2.5% Dextran Sulfate Sodium (DSS) diluted in sterile water was administered negatively for a total of 10 days, and each extract was orally administered for a total of 12 days from 2 days before DSS administration.

i) Normal group: oral administration of sterile water

ii) negative control: 2.5% DSS administration

iii) Experimental group 2-1: 2.5% DSS administration + 20 mg of Cheongdae extract orally administered at a concentration of 50mg/kg

iv) Experimental group 2-2: 2.5% DSS administration + 20 mg of oak leaf extract orally administered at a concentration of 50 mg/kg

v) Experimental group 2-3: 2.5% DSS administration + 20 mg of sputum fruit extract orally administered at a concentration of 50 mg/kg

vi) Experimental group 2-4: 2.5% DSS administration + 10 mg of Cheongdae extract and 10 mg of oak leaf extract were mixed and administered orally at a concentration of 50 mg/kg

vii) Experimental group 2-5: 2.5% DSS administration + 10 mg of Cheongdae extract and 10 mg of sputum fruit extract were mixed and administered orally at a concentration of 50 mg/kg

viii) Experimental group 2-6: 2.5% DSS administration + 6.67mg of Cheongdae extract, 6.67mg of oak leaf extract, and 6.67mg of sputum fruit extract were mixed and administered orally at a concentration of 50mg/kg

[ Experimental example One]

Mouse weight change measurement (1)

Weight loss is a typical symptom of inflammatory bowel disease (Scientific Reports volume 10, Article number: 3829 (2020)). In this experiment, the mouse of Example 1 was weighed once a day at the same time (10 am) using an electronic scale. The rate of change in weight of each group was calculated by summing the weights of 8 mice per group and dividing by 8, and the average weight immediately before the start of 2.5% DSS negative administration was set as 100%, and the average weight of each group was calculated every day to measure the rate of change in weight. I did. The significance was verified by conducting a Mann-Whitney test for each group between the negative control group and the experimental group to which 2.5% DSS was administered negatively.

1A and 1B, the weight of the mice in the normal group was 105.31±1.51%, and the weight of the mice in the negative control group was 81.96±0.84%, which was significantly reduced compared to the normal group. The weight of mice in the positive control group administered 5-ASA was 90.29±1.47%, mice administered only Cheongdae extract (Experimental group 1-1), and 86.19±0.71% body weight, mice administered Cheongdae and Japanese oak extracts (Experimental group 1-2) The body weight was 89.51±1.59%, and the mice administered with extracts of Cheongdae and sputum (Experimental Groups 1-3) were 92.04±1.72%.

From the above results, compared to the extract of Cheongdae alone, Cheongdae and Japanese oak extract and Cheongdae and Phalaenopsis extract had a more excellent weight reduction inhibitory effect, which was found to be similar to the positive control.

[ Experimental example 2]

Mouse weight change measurement (2)

The mice of Example 2 were weighed in the same manner as in Experimental Example 1, and the results are shown in FIG. 2.

As can be seen in FIG. 2, the weight of the mice in the normal group was 104.79±1.36%, and the weight of the mice in the negative control group was 91.16±1.63%, which was significantly reduced compared to the normal group. Mice administered with extracts of Cheongdae and Japanese oak (Experimental Group 2-4), the body weight of mice administered with extracts of Cheongdae and Sputum, 2-5 (Experimental group 2-5) was 93.62±3.09%, and body weight of extracts of Cheongdae, Japanese oak, and Phalaenopsis trees were 93.62±3.09%, and the body weight was 93.62±3.09%. The body weight of mice administered with (Experimental Group 2-6) was 95.89±1.53%.

From the above results, it was found that the Cheongdae and Japanese mulberry extracts, Cheongdae and Salmonaceae extracts, Cheongdae, Japanese mulberry and Salmonaceae extracts all exhibited the effect of inhibiting weight loss in mice, and in particular, showed the most excellent weight loss inhibitory effect in Cheongdae, Japanese mulberry and Salmon tree extracts. Could know.

[ Experimental example 3]

Mouse colon length measurement (1)

It is known that there is a sufficient correlation between the shortening of the large intestine and histological changes, and the length of the large intestine is usually used as a morphological parameter of the degree of inflammation. The mice of Example 1 were sacrificed on the last day of each administration, and the length of the large intestine was measured, and the average length was shown in FIG. 3.

As can be seen in Figure 3, the length of the colon of the normal group was 6.66 ± 0.22 cm, the negative control group was 4.17 ± 0.19 cm, the length of the colon was decreased compared to the normal group. The colon length of the positive control group was 4.41±0.16 cm, the colon length of mice administered only Cheongdae extract (Experimental group 1-1) was 4.25±0.25 cm, and the colon length of mice administered Cheongdae and Japanese oak extracts (Experimental group 1-2) was It was measured to be 4.83±0.17cm.

From the above results, compared to the extract of Cheongdae alone, the length of the large intestine was significantly longer when the extract of Cheongdae and mulberry was administered, which was more excellent than that of the positive control group.

[ Experimental example 4]

Mouse colon length measurement (2)

For the mouse of Example 2, the length of the large intestine was measured in the same manner as in Experimental Example 3, and the results are shown in FIG. 4.

As can be seen in Figure 4, the length of the colon of the normal group was 7.56 ± 0.18 cm, the negative control group was 5.66 ± 0.15 cm, the length of the colon decreased compared to the normal group. Mice administered with Cheongdae and Japanese oak extract (Experimental group 2-4) Colon length was 5.97±0.23 cm, and mice administered with Cheongdae and Sputum extract (Experimental group 2-5) Colon length was 5.76±0.19 cm, Cheongdae, Japanese oak and sputum Mice administered with tree extract (Experimental Group 2-6) The colon length was measured to be 6.23±0.22 cm.

From the above results, Cheongdae and Japanese oak extracts, Cheongdae and Phalaenopsis extracts, Cheongdae, Japanese oak and Phalaenopsis extracts all show the inhibitory effect of reducing the length of the intestine in mice. I could see that it was indicated.

[ Experimental example 5]

Mouse colon weight measurement

Like the length of the large intestine, the weight of the large intestine is also commonly used as a morphological parameter of the degree of inflammation. The mice of Example 2 were sacrificed on the last day of each administration, and the weight of the large intestine was measured, and the average length was shown in FIG. 5.

As can be seen in Figure 5, the weight of the large intestine in the normal group was 0.88±0.01 g, and in the negative control group, 0.59±0.03 g, compared with the normal group, the weight of the large intestine was decreased. Mice administered with Cheongdae and Japanese oak extract (Experimental group 2-4) Large intestine weight 0.65±0.06 g, mice administered with Cheongdae and Sputum extract (Experimental group 2-5) Large intestine weight 0.69±0.05 g, Cheongdae, Japanese oak and sputum The large intestine weight of mice administered with tree extract (Experimental Group 2-6) was measured to be 0.71±0.05g.

From the above results, Cheongdae and Japanese oak extract, Cheongdae and Phalaenopsis extract, Cheongdae, Japanese oak, and Phalaenopsis extract all show the inhibitory effect of reducing the weight of the large intestine in mice, and in particular, the most excellent inhibiting effect of reducing the weight of the large intestine, I could see that it was indicated.

[ Experimental example 6]

Confirmation of reduction in mouse spleen inflammation

A representative condition that can occur in relation to inflammatory bowel disease is splenitis. When the spleen becomes inflamed, the size of the spleen increases due to its nature (Nutrients 2019, 11(11), 2776), and actually induced after DSS treatment. It is known that the spleen becomes enlarged in the IBD model (Biol. Pharm. Bull. 43, 450-457 (2020)).

After the mice of Example 2 were sacrificed on the last day of each administration, the spleen weight and length of each group compared to the negative control group treated with DDS were expressed as a spleen ratio. As can be seen in Figure 6, compared to the normal group, the weight and size of the spleen of the negative control group were increased. Cheongdae (Experimental group 2-1), Japanese oak (Experimental group 2-2), and sputum (Experimental group 2-3) reduced spleen weight and length compared to the negative control group. Experimental group 2-6) The administration group decreased the weight and length of the spleen to a level similar to that of the normal group, and it was found that the symptoms of spleen enlargement due to spleen inflammation were improved.

[ Experimental example 7]

Disease Activity Index, DAI ) Evaluation (1)

In order to measure the intensity of inflammatory bowel disease in the animal model of inflammatory bowel disease treated by the administration method of Example 1, weight change, stool hardening, and the presence or absence of bloody stool visually observed in the stool or anus are shown in Table 1 for disease activity (DAI ) According to the grade, disease activity was measured by checking every day during the administration period.

Disease Activity Index score Weight loss score The shape of the stool score Bloody stool score <1% 0 Hard and hard 0 none 0 1-5% One Hard but sticky One Hidden One 5-10% 2 Smooth but retains shape 2 Visible 2 10-15% 3 Loss of shape while being smooth 3 Rectal bleeding 3 15-20% 4 No form as a liquid 4 - -

As shown in FIGS. 7A and 7B, disease activity was significantly increased in the negative control group administered with DSS. In addition, compared to the Cheongdae extract alone group (Experimental group 1-1), it was confirmed that the disease activity was further improved in the Cheongdae and Japanese oak extract administration group (Experimental group 1-2) and the Cheongdae and sputum extract administration group (Experimental group 1-3). It can be seen that this is a better level than the positive control.

[ Experimental example 8]

Disease Activity Index, DAI ) Evaluation (2)

For the mice of Example 2, disease activity was measured in the same manner as in Experimental Example 7, and the results are shown in FIG. 8.

As can be seen in Figure 8, the disease activity was significantly increased in the negative control group administered with DSS. In addition, compared to the group administered with each single extract of Cheongdae (Experimental Group 2-1), Japanese oak (Experimental group 2-2), and Phalaenopsis (Experimental group 2-3), especially excellent disease activity in the group administered with Cheongdae, Japanese oak and Phalaenopsis extract (Experimental group 2-6). The improvement of was confirmed.

Claims (15)

(1) Cheongdae; And
(2) At least one selected from the group consisting of oak and sputum
Pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a herbal extract of.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the herbal medicine extract is a mixture of extracts extracted from each herbal medicine or extracted from a mixture of herbal medicines.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the mulberry extract is a mulberry leaf extract.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the sputum tree extract is a sputum tree fruit extract.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the herbal extract is extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, and a mixed solvent thereof. .
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the herbal extract is an ethanol extract of 0.01% to 90%.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the herbal extract is an ethanol extract of 60% to 80%.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the pharmaceutical composition comprises herbal extracts of Cheongdae, Japanese oak, and Sputum.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 8, wherein the blending weight ratio of Cheongdae, Japanese oak, and sputum is 1: 0.1 to 10: 0.1 to 10.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 8, wherein the blending weight ratio of Cheongdae, Japanese oak, and sputum is 1: 0.5 to 2: 0.5 to 2.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 8, wherein the blending weight ratio of Cheongdae, Japanese oak, and sputum is 1:1.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the pharmaceutical composition inhibits a decrease in length or weight of the large intestine.
The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 1, wherein the pharmaceutical composition inhibits an increase in length or weight of the spleen.
(1) Cheongdae; And
(2) At least one selected from the group consisting of oak and sputum
A food composition for preventing or improving inflammatory bowel disease, comprising a herbal extract of.
(1) Cheongdae; And
(2) At least one selected from the group consisting of oak and sputum
A feed composition for preventing or improving inflammatory bowel disease, comprising a herbal extract of.

Images